S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Did You See These Trend Reversals? (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Did You See These Trend Reversals? (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Did You See These Trend Reversals? (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Did You See These Trend Reversals? (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:MDRX

Veradigm - MDRX Stock Forecast, Price & News

$13.05
+0.14 (+1.08%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$12.65
$13.05
50-Day Range
$12.89
$18.45
52-Week Range
$12.64
$23.25
Volume
1.62 million shs
Average Volume
1.46 million shs
Market Capitalization
$1.43 billion
P/E Ratio
30.35
Dividend Yield
N/A
Price Target
$20.90

Veradigm MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
60.2% Upside
$20.90 Price Target
Short Interest
Bearish
9.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.65mentions of Veradigm in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
6.25%
From $0.64 to $0.68 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Business Services Sector

130th out of 326 stocks

Computer Integrated Systems Design Industry

12th out of 35 stocks


MDRX stock logo

About Veradigm (NASDAQ:MDRX) Stock

Veradigm, Inc. engages in the provision of clinical, financial, and operational results services. It operates through the Provider and Veradigm segments. The Provider segment includes the hospitals and health systems, ambulatory, CarePort, FollowMyHealth, EPSiTM, EISClassics, and 2bPrecise strategic business units. The firm solutions include All EMRs, All Population Health Management, Patient Engagement, and Precision Medicine. The company was founded in 1986 and is headquartered in Chicago, IL.

Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

MDRX Stock News Headlines

Veradigm (NASDAQ:MDRX) Issues FY23 Earnings Guidance
Veradigm (NASDAQ:MDRX) Releases FY 2023 Earnings Guidance
What To Do With Your Trades Today
There’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts pixel
5 Hypergrowth Stocks to Buy Now
Luke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. pixel
Veradigm Announces Two New Appointments to Its Board
Veradigm Building Momentum Across All Markets
Veradigm Announces Strategic Investment in Holmusk
SVB Securities Reaffirms Their Buy Rating on Allscripts (MDRX)
See More Headlines
Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

MDRX Company Calendar

Last Earnings
11/04/2021
Today
4/01/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Computer integrated systems design
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:MDRX
CUSIP
01988P10
Employees
8,000
Year Founded
1986

Price Target and Rating

Average Stock Price Forecast
$20.90
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+60.2%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$134.44 million
Pretax Margin
14.59%

Debt

Sales & Book Value

Annual Sales
$1.50 billion
Cash Flow
$2.77 per share
Book Value
$11.49 per share

Miscellaneous

Free Float
106,758,000
Market Cap
$1.43 billion
Optionable
Optionable
Beta
1.01

Social Links


Key Executives

  • Richard J. PoultonRichard J. Poulton
    Chief Executive Officer & Director
  • Thomas Langan
    President
  • Rick Dipper
    Chief of Staff & Head-Business Operations
  • Leah Jones
    Chief Financial & Accounting Officer
  • Joseph R. Rostock
    Chief Technology Officer & SVP-Product Engineering













MDRX Stock - Frequently Asked Questions

Should I buy or sell Veradigm stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings
or view top-rated stocks.

What is Veradigm's stock price forecast for 2023?

5 Wall Street analysts have issued 1-year price objectives for Veradigm's shares. Their MDRX share price forecasts range from $17.00 to $26.00. On average, they predict the company's stock price to reach $20.90 in the next twelve months. This suggests a possible upside of 60.2% from the stock's current price.
View analysts price targets for MDRX
or view top-rated stocks among Wall Street analysts.

How have MDRX shares performed in 2023?

Veradigm's stock was trading at $17.64 at the beginning of the year. Since then, MDRX stock has decreased by 26.0% and is now trading at $13.05.
View the best growth stocks for 2023 here
.

When is Veradigm's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our MDRX earnings forecast
.

How were Veradigm's earnings last quarter?

Veradigm Inc. (NASDAQ:MDRX) released its quarterly earnings results on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. The software maker earned $369 million during the quarter, compared to analyst estimates of $376.09 million. Veradigm had a net margin of 7.25% and a trailing twelve-month return on equity of 10.74%. Veradigm's quarterly revenue was down 8.2% on a year-over-year basis. During the same period last year, the company earned $0.15 earnings per share.

How will Veradigm's stock buyback program work?

Veradigm declared that its Board of Directors has authorized a stock repurchase program on Wednesday, May 26th 2021, which authorizes the company to repurchase $350,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 14% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board believes its shares are undervalued.

What guidance has Veradigm issued on next quarter's earnings?

Veradigm issued an update on its FY 2023 earnings guidance on Wednesday, March, 22nd. The company provided earnings per share (EPS) guidance of $0.80-$0.90 for the period, compared to the consensus EPS estimate of $0.90. The company issued revenue guidance of $615.00 million-$635.00 million, compared to the consensus revenue estimate of $649.05 million.

What is Paul Black's approval rating as Veradigm's CEO?

796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Veradigm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

What is Veradigm's stock symbol?

Veradigm trades on the NASDAQ under the ticker symbol "MDRX."

How do I buy shares of Veradigm?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veradigm's stock price today?

One share of MDRX stock can currently be purchased for approximately $13.05.

How much money does Veradigm make?

Veradigm (NASDAQ:MDRX) has a market capitalization of $1.43 billion and generates $1.50 billion in revenue each year. The software maker earns $134.44 million in net income (profit) each year or $0.43 on an earnings per share basis.

How many employees does Veradigm have?

The company employs 8,000 workers across the globe.

Does Veradigm have any subsidiaries?
The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx.
Read More
How can I contact Veradigm?

Veradigm's mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The official website for the company is www.allscripts.com. The software maker can be reached via phone at (800) 334-8534, via email at stephen.shulstein@allscripts.com, or via fax at 313-322-9600.

This page (NASDAQ:MDRX) was last updated on 4/1/2023 by MarketBeat.com Staff